Shares of Akero Therapeutics (NASDAQ:AKRO) have earned an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $54.40.
A number of brokerages recently issued reports on AKRO. Canaccord Genuity boosted their price objective on Akero Therapeutics from $36.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Jefferies Financial Group boosted their price objective on Akero Therapeutics from $31.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. HC Wainwright upped their price target on Akero Therapeutics from $45.00 to $62.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. ValuEngine downgraded Akero Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, Zacks Investment Research downgraded Akero Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 23rd.
In other news, Director Kevin Bitterman sold 13,000 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $28.93, for a total transaction of $376,090.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.09% of the stock is owned by corporate insiders.
Akero Therapeutics stock opened at $28.35 on Thursday. The business has a 50-day simple moving average of $32.09 and a two-hundred day simple moving average of $28.78. The company has a market cap of $983.77 million, a P/E ratio of -13.50 and a beta of 0.54. Akero Therapeutics has a 52-week low of $10.78 and a 52-week high of $41.16.
Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.09. On average, equities research analysts forecast that Akero Therapeutics will post -2.51 EPS for the current fiscal year.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Recommended Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.